How to Move Forward After a Thumbs Down from FDA
Interview with Kevin Sidow, Former CEO and President of Moximed
In late 2016, I was able to sit down with Kevin Sidow. At the time, he was President & Chief Executive Officer for Moximed, and had been since 2008.
Prior to his time at Moximed, Kevin was President & CEO for St. Francis Medical Technologies, a privately held, venture-funded company focused on developing innovative treatments for patients suffering from degenerative spinal disorders. In January 2007, St. Francis Medical Technologies was sold for $725 million to Kyphon, which was acquired by Medtronic later that same year.
Previously, Kevin was the Worldwide President of DePuy, where he supervised the global orthopedic, spine, trauma, and sports medicine businesses, with annual revenue responsibility of over $3 billion dollars. Kevin holds a B.S. in Accounting from West Virginia University.
Interview Highlights with Kevin Sidow
How Kevin felt when Moximed’s first patient was treated with the Atlas System after 8+ years of research and development.
What makes the Atlas System different than other orthopedic knee implants.
How medtech professionals looking to take the next step in their career can utilize Kevin’s advice and learn from his meteoric rise to Worldwide President of DePuy.
How Kevin and his team responded when their device received an unfavorable response from an FDA panel.
Kevin’s approach to financing a medtech startup after raising nearly $100M to fund Moximed.
Kevin’s favorite business book, the CEO he most admires, and the advice he’d give to his 25-year-old self.
You May Like These Articles
Medsider Premium
Become a premium member and unlock access to exclusive Medsider benefits.